Wang Jin, Zhao Xiaomu, Jin Lan, Wu Guocong, Yang Yingchi
Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, 95 Yongan Road, Xicheng District, Beijing, 100050, China.
Dig Dis Sci. 2017 Oct;62(10):2781-2789. doi: 10.1007/s10620-017-4732-6. Epub 2017 Aug 30.
The E3 ligase UBR5 is aberrantly expressed in diverse types of cancer. However, its expression pattern and biological function in colorectal cancer (CRC) remain unclear.
We used RT-PCR, Western blot, and immunohistochemistry to measure UBR5 expression in CRC tissues and corresponding non-tumor tissues. The expression pattern of UBR5 in CRC tissues was determined by scoring system of immunohistochemical analysis and mRNA level by RT-PCR. The statistical analyses were applied to evaluate the associations of UBR5 expression with survival rate of patients. The UBR5 gene was overexpressed or silenced with lentiviral vectors in CRC cells. And, cell proliferation and apoptosis were measured using CCK8 assay and flow cytometry.
We found that UBR5 is abundantly overexpressed in CRC tissues than adjacent non-cancerous tissues. We also found that high UBR5 level is positively correlated with progression and poor survival in CRC patients. In addition, further multivariate analysis indicated that UBR5 and TNM stage were independent prognostic factors for overall survival in patients with CRC. Furthermore, we demonstrated that the expression of UBR5 was significantly elevated in CRC cell lines. Overexpression of UBR5 enhanced in vitro cell proliferation and promoted in vivo tumor growth, whereas silencing UBR5 suppressed growth of CRC cells. Moreover, our findings show that UBR5 promotes CRC cell proliferation by inducing cell cycle progression and suppressing cell apoptosis. Finally, we found that UBR5 directly binds to the tumor suppressor esophageal cancer-related gene 4 (ECRG4) and increased its ubiquitination to reduce the protein stability of ECRG4.
We identified a tumorigenic role of UBR5 in CRC and provided a novel therapeutic target for CRC patients.
E3泛素连接酶UBR5在多种癌症中异常表达。然而,其在结直肠癌(CRC)中的表达模式和生物学功能仍不清楚。
我们使用逆转录聚合酶链反应(RT-PCR)、蛋白质免疫印迹法和免疫组织化学来检测CRC组织及相应非肿瘤组织中UBR5的表达。通过免疫组织化学分析评分系统确定CRC组织中UBR5的表达模式,通过RT-PCR确定mRNA水平。应用统计学分析评估UBR5表达与患者生存率的相关性。使用慢病毒载体在CRC细胞中过表达或沉默UBR5基因。并且,使用CCK8法和流式细胞术检测细胞增殖和凋亡。
我们发现CRC组织中UBR5的表达明显高于相邻的非癌组织。我们还发现高UBR5水平与CRC患者的病情进展和不良生存呈正相关。此外,进一步的多因素分析表明,UBR5和TNM分期是CRC患者总生存的独立预后因素。此外,我们证明CRC细胞系中UBR5的表达显著升高。UBR5的过表达增强了体外细胞增殖并促进了体内肿瘤生长,而沉默UBR5则抑制了CRC细胞的生长。此外,我们的研究结果表明,UBR5通过诱导细胞周期进程和抑制细胞凋亡来促进CRC细胞增殖。最后,我们发现UBR5直接与肿瘤抑制因子食管癌相关基因4(ECRG4)结合,并增加其泛素化以降低ECRG4的蛋白质稳定性。
我们确定了UBR5在CRC中的致癌作用,并为CRC患者提供了一个新的治疗靶点。